- Home
- SPR vs SWTX Comparison
SPR vs SWTX Comparison
Compare SPR & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPR
- SWTX
- Stock Information
- Founded
- SPR 1927
- SWTX 2017
- Country
- SPR United States
- SWTX United States
- Employees
- SPR N/A
- SWTX N/A
- Industry
- SPR Military/Government/Technical
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPR Industrials
- SWTX Health Care
- Exchange
- SPR Nasdaq
- SWTX Nasdaq
- Market Cap
- SPR 4.3B
- SWTX 3.5B
- IPO Year
- SPR 2006
- SWTX 2019
- Fundamental
- Price
- SPR $38.22
- SWTX $47.00
- Analyst Decision
- SPR Hold
- SWTX Buy
- Analyst Count
- SPR 11
- SWTX 7
- Target Price
- SPR $36.56
- SWTX $56.86
- AVG Volume (30 Days)
- SPR 1.3M
- SWTX 4.5M
- Earning Date
- SPR 08-04-2025
- SWTX 08-06-2025
- Dividend Yield
- SPR N/A
- SWTX N/A
- EPS Growth
- SPR N/A
- SWTX N/A
- EPS
- SPR N/A
- SWTX N/A
- Revenue
- SPR $6,135,600,000.00
- SWTX $219,670,000.00
- Revenue This Year
- SPR $23.93
- SWTX $74.36
- Revenue Next Year
- SPR $14.86
- SWTX $75.63
- P/E Ratio
- SPR N/A
- SWTX N/A
- Revenue Growth
- SPR N/A
- SWTX 730.42
- 52 Week Low
- SPR $27.00
- SWTX $28.21
- 52 Week High
- SPR $39.00
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- SPR 52.86
- SWTX 63.86
- Support Level
- SPR $36.71
- SWTX $46.93
- Resistance Level
- SPR $37.53
- SWTX $47.02
- Average True Range (ATR)
- SPR 0.56
- SWTX 0.08
- MACD
- SPR -0.12
- SWTX -0.06
- Stochastic Oscillator
- SPR 28.60
- SWTX 90.32
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.